Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis Bourgeois

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Msphere|July 14, 2021
<i>Shigella</i>-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonneiKristen A Clarkson, Chad K Porter, Kawsar R Talaat, et al.
Vaccine|November 13, 2021
Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infantsAnn-Mari Svennerholm, Firdausi Qadri, Anna Lundgren, et al.
Current Topics in Microbiology and Immunology|October 20, 2021
The Controlled Human Infection Model for Enterotoxigenic Escherichia coliChad K Porter, Kawsar R Talaat, Sandra D Isidean, et al.
Clinical and Vaccine Immunology : CVI|October 5, 2012
The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal diseaseMichael J Darsley, Subhra Chakraborty, Barbara DeNearing, et al.
Vaccine|March 17, 2023
Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert conveningMark S Riddle, A Louis Bourgeois, Allison Clifford, et al.
Vaccine|October 12, 2023
Vaccine value profile for ShigellaWilliam P Hausdorff, John D Anderson, Karoun H Bagamian, et al.
Frontiers in Cellular and Infection Microbiology|September 7, 2021
Linking inherent O-Linked Protein Glycosylation of YghJ to Increased Antigen PotentialMette Thorsing, Thøger Jensen Krogh, Lars Vitved, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Clinical EndpointsCalman A MacLennan, Mark S Riddle, Wilbur H Chen, et al.
Clinical and Vaccine Immunology : CVI|September 20, 2013
Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coliSamer S El-Kamary, Mitchell B Cohen, A Louis Bourgeois, et al.
Plos Neglected Tropical Diseases|April 28, 2018
Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteersSubhra Chakraborty, Clayton Harro, Barbara DeNearing, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Msphere|July 14, 2021
<i>Shigella</i>-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonneiKristen A Clarkson, Chad K Porter, Kawsar R Talaat, et al.
Vaccine|November 13, 2021
Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infantsAnn-Mari Svennerholm, Firdausi Qadri, Anna Lundgren, et al.
Current Topics in Microbiology and Immunology|October 20, 2021
The Controlled Human Infection Model for Enterotoxigenic Escherichia coliChad K Porter, Kawsar R Talaat, Sandra D Isidean, et al.
Clinical and Vaccine Immunology : CVI|October 5, 2012
The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal diseaseMichael J Darsley, Subhra Chakraborty, Barbara DeNearing, et al.
Vaccine|March 17, 2023
Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert conveningMark S Riddle, A Louis Bourgeois, Allison Clifford, et al.
Vaccine|October 12, 2023
Vaccine value profile for ShigellaWilliam P Hausdorff, John D Anderson, Karoun H Bagamian, et al.
Frontiers in Cellular and Infection Microbiology|September 7, 2021
Linking inherent O-Linked Protein Glycosylation of YghJ to Increased Antigen PotentialMette Thorsing, Thøger Jensen Krogh, Lars Vitved, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Clinical EndpointsCalman A MacLennan, Mark S Riddle, Wilbur H Chen, et al.
Clinical and Vaccine Immunology : CVI|September 20, 2013
Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coliSamer S El-Kamary, Mitchell B Cohen, A Louis Bourgeois, et al.
Plos Neglected Tropical Diseases|April 28, 2018
Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteersSubhra Chakraborty, Clayton Harro, Barbara DeNearing, et al.
Pageof 7